Dark

Check out our API

ATNFW
180 Life Sciences Corp. Warrant
stock NASDAQ

Inactive

Aug 15, 2025

0.4300USD-6.522%(-0.0300)1,650,889

Pre-market

0.00USD-100.000%(-0.46)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Feb 24, 2021

04:00PM EST 180 Life Sciences Corp. Announces Closing of $11.7 Million Private GlobeNewswire Inc

Feb 19, 2021

09:00AM EST 180 Life Sciences Corp. Announces $11.7 Million Private Placement GlobeNewswire Inc

Jan 5, 2021

02:50PM EST 180 Life Sciences Corp. (NASDAQ:ATNF)(180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that the Company will present at the H.C. Wainwright Bioconnect 2021 Conference. GlobeNewswire Inc

Dec 3, 2020

11:08AM EST 180 Life Sciences Corp. (NASDAQ:ATNF)("180 Life Sciences" or "the Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced it will participate in the LD Micro Virtual Main Event 2020 Conference. GlobeNewswire Inc

Nov 24, 2020

10:00AM EST 180 Life Sciences Corp. to Ring Nasdaq Opening Bell on November GlobeNewswire Inc

Nov 23, 2020

08:30AM EST 180 Life Sciences Corp. (NASDAQ:ATNFor the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the continued expansion of its IP portfolio. GlobeNewswire Inc

Nov 17, 2020

08:00AM EST 180 Life Sciences Corp. (NASDAQ:ATNFor the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today released the following letter to stockholders from its Chief Executive Officer, Dr. James Woody. GlobeNewswire Inc

Nov 10, 2020

11:46AM EST 180 Life Sciences Corp. (NASDAQ:ATNFor the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the successful closing of its transaction with KBL Merger Corp IV. GlobeNewswire Inc

Share